BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 24019170)

  • 1. NKG2D regulates production of soluble TRAIL by ex vivo expanded human γδ T cells.
    Dokouhaki P; Schuh NW; Joe B; Allen CA; Der SD; Tsao MS; Zhang L
    Eur J Immunol; 2013 Dec; 43(12):3175-82. PubMed ID: 24019170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
    Zhang T; Sentman CL
    Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-17a-producing γδT cells and NKG2D signaling mediate bacterial endotoxin-induced neonatal lung injury: implications for bronchopulmonary dysplasia.
    Cui TX; Brady AE; Zhang YJ; Anderson C; Popova AP
    Front Immunol; 2023; 14():1156842. PubMed ID: 37744375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes.
    Lai D; Wang F; Chen Y; Wang C; Liu S; Lu B; Ge X; Guo L
    Cancer Immunol Immunother; 2012 Jul; 61(7):979-89. PubMed ID: 22120758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Searching for "signal 2": costimulation requirements of γδ T cells.
    Ribot JC; debarros A; Silva-Santos B
    Cell Mol Life Sci; 2011 Jul; 68(14):2345-55. PubMed ID: 21541698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation.
    Pereboeva L; Harkins L; Wong S; Lamb LS
    Cancer Immunol Immunother; 2015 May; 64(5):551-62. PubMed ID: 25676710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of IL-2 receptor alpha (CD25) characterizes human gammadelta-T cells rendered resistant to apoptosis after CD2 engagement in the presence of IL-12.
    Guo BL; Hollmig KA; Lopez RD
    Cancer Immunol Immunother; 2002 Jan; 50(11):625-37. PubMed ID: 11807626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Special Connection between γδ T Cells and Natural Antibodies?
    Born WK; Huang Y; Zeng W; Torres RM; O'Brien RL
    Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(6):455-462. PubMed ID: 27235134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells.
    Hernández-López P; van Diest E; Brazda P; Heijhuurs S; Meringa A; Hoorens van Heyningen L; Riillo C; Schwenzel C; Zintchenko M; Johanna I; Nicolasen MJT; Cleven A; Kluiver TA; Millen R; Zheng J; Karaiskaki F; Straetemans T; Clevers H; de Bree R; Stunnenberg HG; Peng WC; Roodhart J; Minguet S; Sebestyén Z; Beringer DX; Kuball J
    Nat Immunol; 2024 Jan; 25(1):88-101. PubMed ID: 38012415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial Expression of Concern: MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.
    Garofalo M; Quintavalle C; Di Leva G; Zanca C; Romano G; Taccioli C; Liu CG; Croce CM; Condorelli G
    Oncogene; 2024 Mar; 43(14):1075. PubMed ID: 38418545
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer of unknown primary site.
    Vajdic CM; Goldstein D
    Aust Fam Physician; 2015 Sep; 44(9):640-3. PubMed ID: 26488041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer.
    Silva-Santos B; Mensurado S; Coffelt SB
    Nat Rev Cancer; 2019 Jul; 19(7):392-404. PubMed ID: 31209264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The capability of heterogeneous γδ T cells in cancer treatment.
    Yan W; Dunmall LSC; Lemoine NR; Wang Y; Wang Y; Wang P
    Front Immunol; 2023; 14():1285801. PubMed ID: 38077392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary analysis of double-negative T, double-positive T, and natural killer T-like cells in B-cell chronic lymphocytic leukemia.
    Valvano L; Nozza F; D'Arena G; D'Auria F; De Luca L; Pietrantuono G; Mansueto G; Villani O; D'Agostino S; Lamorte D; Calice G; Statuto T
    Cancer Med; 2023 Jun; 12(12):13241-13255. PubMed ID: 37140360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer Stem Cell-Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands.
    Raute K; Strietz J; Parigiani MA; Andrieux G; Thomas OS; Kistner KM; Zintchenko M; Aichele P; Hofmann M; Zhou H; Weber W; Boerries M; Swamy M; Maurer J; Minguet S
    Cancer Immunol Res; 2023 Jun; 11(6):810-829. PubMed ID: 37139603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate lymphoid cells and innate-like T cells in cancer - at the crossroads of innate and adaptive immunity.
    Ruf B; Greten TF; Korangy F
    Nat Rev Cancer; 2023 Jun; 23(6):351-371. PubMed ID: 37081117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging roles of γδ T cells in cancer immunotherapy.
    Mensurado S; Blanco-Domínguez R; Silva-Santos B
    Nat Rev Clin Oncol; 2023 Mar; 20(3):178-191. PubMed ID: 36624304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the Seasonal Fluctuation of γδ T Cells and Its Potential Relation with Vitamin D
    Bernicke B; Engelbogen N; Klein K; Franzenburg J; Borzikowsky C; Peters C; Janssen O; Junker R; Serrano R; Kabelitz D
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innate Immunity and Cancer Pathophysiology.
    Maiorino L; Daßler-Plenker J; Sun L; Egeblad M
    Annu Rev Pathol; 2022 Jan; 17():425-457. PubMed ID: 34788549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation and Functions of Protumoral Unconventional T Cells in Solid Tumors.
    Barsac E; de Amat Herbozo C; Gonzalez L; Baranek T; Mallevaey T; Paget C
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.